Hydrocodone was patented in 1923, while the long-acting formulation was approved for medical use in the United States in 2013.[10][17] It is most commonly prescribed in the United States, which consumed 99% of the worldwide supply as of 2010.[18] In 2018, it was the 402nd most commonly prescribed medication in the United States, with more than 400,000 prescriptions.[19] Hydrocodone is a semi-synthetic opioid, converted fromcodeine[20][21] or less often fromthebaine.[22] Production using genetically engineered yeasts has been developed but is not used commercially.[23][24][25]
Hydrocodone is used to treat moderate to severe pain. In liquid formulations, it is used to treat coughing.[10] In one study comparing the potency of hydrocodone to that ofoxycodone, it was found that it took 50% more hydrocodone to achieve the same degree of miosis (pupillary contraction).[26] The investigators interpreted this to mean that oxycodone is about 50% more potent than hydrocodone.
However, in a study ofemergency department patients with fractures, it was found that an equal amount of either drug provided about the same degree of pain relief, indicating that there is little practical difference between them when used for that purpose.[27] Some references state that the analgesic action of hydrocodone begins in 20–30 minutes and lasts about 4–8 hours.[28] The manufacturer's information says onset of action is about 10–30 minutes and duration is about 4–6 hours.[29] Recommended dosing interval is 4–6 hours. Hydrocodone reaches peak serum levels after 1.3 hours.[30]
Hydrocodone is available in a variety of formulations for oral administration:[31][32][33]
The original oral form of hydrocodone alone, Dicodid, as immediate-release 5- and 10-mg tablets is available for prescription in Continental Europe per national drug control and prescription laws and Title 76 of the Schengen Treaty, butdihydrocodeine has been more widely used for the same indications since the beginning in the early 1920s, with hydrocodone being regulated the same way asmorphine in the GermanBetäubungsmittelgesetz, the similarly named law in Switzerland and the AustrianSuchtmittelgesetz, whereas dihydrocodeine is regulated likecodeine. For a number of decades, the liquid hydrocodone products available have been cough medicines.
Hydrocodone plushomatropine (Hycodan) in the form of small tablets for coughing and especially neuropathic moderate pain (the homatropine, an anticholinergic, is useful in both of those cases and is a deterrent to intentional overdose) was more widely used than Dicodid and was labelled as a cough medicine in the United States whilst Vicodin and similar drugs were the choices for analgesia.
Extended-release hydrocodone in a time-release syrup also containing chlorphenamine/chlorpheniramine is a cough medicine called Tussionex in North America. In Europe, similar time-release syrups containing codeine (numerous), dihydrocodeine (Paracodin Retard Hustensaft), nicocodeine (Tusscodin),thebacon,acetyldihydrocodeine,dionine, andnicodicodeine are used instead.
Several cases of progressive bilateral hearing loss unresponsive to steroid therapy have been described as an infrequent adverse reaction to hydrocodone/paracetamol misuse. This adverse effect has been considered by some to be due to theototoxicity of hydrocodone.[36][37] Other researchers have suggested that paracetamol is the primary agent responsible for the ototoxicity.[38][39]
The U.S.Food and Drug Administration (FDA) assigns the drug topregnancy category C, meaning that no adequate and well-controlled studies in humans have been conducted. A newborn of a mother taking opioid medications regularly prior to the birth will be physically dependent.[40][41] The baby may also exhibit respiratory depression if the opioid dose was high.[42] An epidemiological study indicated that opioid treatment during early pregnancy results in increased risk of various birth defects.[43]
Symptoms of hydrocodoneoverdose include narrowed or widened pupils; slow, shallow, or stopped breathing; slowed or stopped heartbeat; cold, clammy, or blue skin; excessive sleepiness; loss of consciousness; seizures; or death.[35]
Hydrocodone can be habit forming, causing physical and psychological dependence. Its abuse liability is similar to morphine and less than oxycodone.[44]
Studies have shown hydrocodone is stronger thancodeine but only one-tenth as potent asmorphine at binding to receptors and reported to be only 59% as potent as morphine in analgesic properties. However, in tests conducted on rhesus monkeys, the analgesic potency of hydrocodone was actually higher than morphine.[7]Oral hydrocodone has a mean equivalent daily dosage (MEDD) factor of 0.4, meaning that 1 mg of hydrocodone is equivalent to 0.4 mg of intravenous morphine. However, because of morphine's loworal bioavailability, there is a 1:1 correspondence between orally administered morphine and orally administered hydrocodone.[56]
Hydrocodone is only pharmaceutically available as anoral medication.[2] It is well-absorbed, but the oralbioavailability of hydrocodone is only approximately 25%.[4][5] Theonset of action of hydrocodone via this route is 10 to 20 minutes, with a peak effect (Tmax) occurring at 30 to 60 minutes,[51] and it has a duration of 4 to 8 hours.[2] The FDA label for immediate-release hydrocodone with acetaminophen does not include any information on the influence of food on its absorption or other pharmacokinetics.[57] Conversely, coadministration with a high-fat meal increases peak concentrations of different formulations of extended-release hydrocodone by 14 to 54%, whereasarea-under-the-curve levels are not notably affected.[58][59][60][61]
In theliver, hydrocodone is transformed into severalmetabolites, includingnorhydrocodone,hydromorphone,6α-hydrocodol (dihydrocodeine), and6β-hydrocodol.[6] 6α- and 6β-hydromorphol are also formed, and the metabolites of hydrocodone are conjugated (viaglucuronidation).[62][63] Hydrocodone has aterminal half-life that averages 3.8 hours (range 3.3–4.4 hours).[7][2] The hepaticcytochrome P450 enzymeCYP2D6 converts hydrocodone into hydromorphone, a more potent opioid (5-fold higher binding affinity to the MOR).[6][64] However, extensive and poorcytochrome 450 CYP2D6 metabolizers had similar physiological and subjective responses to hydrocodone, and CYP2D6 inhibitorquinidine did not change the responses of extensive metabolizers, suggesting that inhibition of CYP2D6 metabolism of hydrocodone has no practical importance.[65][66] Ultra-rapid CYP2D6 metabolizers (1–2% of the population) may have an increased response to hydrocodone; however, hydrocodone metabolism in this population has not been studied.[67]
Norhydrocodone, the major metabolite of hydrocodone, is predominantly formed by CYP3A4-catalyzed oxidation.[6] In contrast to hydromorphone, it is described as inactive.[64] However, norhydrocodone is actually a MOR agonist with similar potency to hydrocodone, but has been found to produce only minimal analgesia when administered peripherally to animals (likely due to poorblood–brain barrier and thuscentral nervous system penetration).[68] Inhibition of CYP3A4 in a child who was, in addition, a poor CYP2D6 metabolizer, resulted in a fatal overdose of hydrocodone.[69] Approximately 40% of hydrocodone metabolism is attributed to non-cytochrome P450-catalyzed reactions.[70]
Hydrocodone concentrations are measured in blood, plasma, and urine to seek evidence of misuse, to confirm diagnoses of poisoning, and to assist in investigations into deaths. Many commercial opiate screening tests react indiscriminately with hydrocodone, other opiates, and their metabolites, but chromatographic techniques can easily distinguish hydrocodone uniquely. Blood and plasma hydrocodone concentrations typically fall into the 5–30 μg/L range among people taking the drug therapeutically, 100–200 μg/L among recreational users, and 100–1,600 μg/L in cases of acute, fatal overdosage. Co-administration of the drug with food or alcohol can very significantly increase the resulting plasma hydrocodone concentrations that are subsequently achieved.[71][72]
Hydrocodone is most commonly synthesized fromthebaine, a constituent of opium latex from the dried poppy plant. Once thebaine is obtained, the reaction undergoeshydrogenation using a palladium catalyst.[73]
There are three important structures in hydrocodone: theamine group, which binds to the tertiary nitrogen binding site in the central nervous system'sopioid receptor, thehydroxy group that binds to the anionic binding site, and thephenyl group which binds to the phenolic binding site.[74] This triggers a G protein activation and subsequent release ofdopamine.[75]
Hydrocodone was first synthesized in Germany in 1920 byCarl Mannich and Helene Löwenheim.[76] It was approved by theFood and Drug Administration on 23 March 1943 for sale in the United States and approved byHealth Canada for sale in Canada under the brand name Hycodan.[77][78]
Hydrocodone was first marketed by Knoll as Dicodid, starting in February 1924 in Germany. This name is analogous to other products the company introduced or otherwise marketed: Dilaudid (hydromorphone, 1926), Dinarkon (oxycodone, 1917), Dihydrin (dihydrocodeine, 1911), and Dimorphan (dihydromorphine). Paramorfan is the trade name of dihydromorphine from another manufacturer, as is Paracodin, for dihydrocodeine.[79][80]
Hydrocodone was patented in 1923, while the long-acting formulation was approved for medical use in the United States in 2013.[10][17] It is most commonly prescribed in the United States, which consumed 99% of the worldwide supply as of 2010.[81] In 2018, it was the 402nd most commonly prescribed medication in the United States, with more than 400,000 prescriptions.[19]
Hydrocodone and paracetamol (acetaminophen) 10-325 tablets (Mallinckrodt)
Most hydrocodone formulations include a second analgesic, such as paracetamol (acetaminophen) or ibuprofen. Examples of hydrocodone combinations include Norco, Vicodin, Vicoprofen and Riboxen.[83]
The US government imposed tougher prescribing rules for hydrocodone in 2014, changing the drug fromSchedule III toSchedule II.[84][85][86][87] In 2011, hydrocodone products were involved in around 100,000 abuse-related emergency department visits in the United States, more than double the number in 2004.[88]
Hydrocodone is predominantly used as anantitussive in dogs. Hydrocodone has low oral bioavailability and provide poor analgesia in cats and dogs. One study in dogs found hydrocodone to be less effective thanfirocoxib for dogs undergoing atibial-plateau-levelling osteotomy.[89]
^abcPolsten GR, Wallace MS (21 June 2016)."Analgesic Agents in Rheumatic Disease". In Firestein GS, Budd R, Gabriel SE, McInnes IB, O'Dell JR (eds.).Kelley and Firestein's Textbook of Rheumatology. Elsevier Health Sciences. pp. 1081–.ISBN978-0-323-41494-4.Archived from the original on 12 January 2023. Retrieved23 September 2016.
^Narcotic Drugs 2020, Estimated World Requirements for 2021, Statistics for 2019(PDF). International Narcotics Control Board. 2020. p. 37.ISBN978-92-1-148355-0.Archived(PDF) from the original on 3 November 2021. Retrieved12 December 2021.Thebaine itself is not used in therapy, but it is an important starting material for the manufacture of a number of opioids, mainly codeine, dihydrocodeine, etorphine, hydrocodone, oxycodone and oxymorphone...
^McPherson ML (24 August 2009)."Appendix: Opioid Formulations".Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing. ASHP. pp. 187–188.ISBN978-1-58528-297-5.Archived from the original on 12 January 2023. Retrieved23 September 2016.
^Skidmore-Roth L (27 June 2013)."Hydrocodone".Mosby's Drug Guide for Nursing Students, with 2014 Update. Elsevier Health Sciences. pp. 524–.ISBN978-0-323-22268-6.Archived from the original on 12 January 2023. Retrieved23 September 2016.
^Friedman RA, House JW, Luxford WM, Gherini S, Mills D (March 2000). "Profound hearing loss associated with hydrocodone/acetaminophen abuse".The American Journal of Otology.21 (2):188–191.doi:10.1016/S0196-0709(00)80007-1 (inactive 31 July 2025).PMID10733182.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
^Yorgason JG, Kalinec GM, Luxford WM, Warren FM, Kalinec F (June 2010). "Acetaminophen ototoxicity after acetaminophen/hydrocodone abuse: evidence from two parallel in vitro mouse models".Otolaryngology–Head and Neck Surgery.142 (6):814–9, 819.e1–2.doi:10.1016/j.otohns.2010.01.010.PMID20493351.S2CID25083914.
^Gnanadesigan N, Espinoza RT, Smith RL (June 2005). "The serotonin syndrome".The New England Journal of Medicine.352 (23):2454–6, author reply 2454–6.doi:10.1056/NEJM200506093522320.PMID15948273.
^Filizola M, Villar HO, Loew GH (January 2001). "Molecular determinants of non-specific recognition of delta, mu, and kappa opioid receptors".Bioorganic & Medicinal Chemistry.9 (1):69–76.doi:10.1016/S0968-0896(00)00223-6.PMID11197347.
^Tiziani AP (1 June 2013)."Opiod Analgesics".Havard's Nursing Guide to Drugs. Elsevier Health Sciences. pp. 933–.ISBN978-0-7295-8162-2.Archived from the original on 11 January 2023. Retrieved22 June 2018.
^Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE (February 2004). "Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors".The Journal of Pharmacology and Experimental Therapeutics.308 (2):547–554.doi:10.1124/jpet.103.058602.PMID14600248.S2CID22492018.
^Agar M, Clark K (10 February 2015)."Palliative Medicine". In Talley NJ, Frankum B, Currow D (eds.).Essentials of Internal Medicine (3rd ed.). Elsevier Health Sciences. pp. 491–.ISBN978-0-7295-8081-6.
^Raffa RB, Colucci R, Pergolizzi JV (September 2017). "The effects of food on opioid-induced nausea and vomiting and pharmacological parameters: a systematic review".Postgraduate Medicine.129 (7):698–708.doi:10.1080/00325481.2017.1345282.PMID28635354.S2CID46184629.
^Bond M, Rabinovich-Guilatt L, Selim S, Darwish M, Tracewell W, Robertson P, et al. (December 2017). "Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects".Clinical Drug Investigation.37 (12):1153–1163.doi:10.1007/s40261-017-0575-3.PMID28948482.S2CID32440860.
^Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, et al. (April 1997). "Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability".The Journal of Pharmacology and Experimental Therapeutics.281 (1):103–108.doi:10.1016/S0022-3565(24)36599-1.PMID9103485.
^Gardiner SJ, Begg EJ (September 2006). "Pharmacogenetics, drug-metabolizing enzymes, and clinical practice".Pharmacological Reviews.58 (3):521–590.doi:10.1124/pr.58.3.6.PMID16968950.S2CID25747320.
^Navani DM, Yoburn BC (November 2013). "In vivo activity of norhydrocodone: an active metabolite of hydrocodone".The Journal of Pharmacology and Experimental Therapeutics.347 (2):497–505.doi:10.1124/jpet.113.207548.PMID23995596.S2CID31072872.
^Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, et al. (October 2010). "Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions".Pediatrics.126 (4):e986 –e989.doi:10.1542/peds.2009-1907.PMID20837591.S2CID42365304.
^Spiller HA (March 2003). "Postmortem oxycodone and hydrocodone blood concentrations".Journal of Forensic Sciences.48 (2):429–431.doi:10.1520/JFS2002309.PMID12665006.
^Simon BT, Lizarraga I (11 September 2024). "Opioids". In Lamont L, Grimm K, Robertson S, Love L, Schroeder C (eds.).Veterinary Anesthesia and Analgesia, The 6th Edition of Lumb and Jones. Wiley Blackwell. p. 381.ISBN978-1-119-83027-6.
